Structure-based design of targeted covalent inhibitors
The DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
Abstract
Covalent inhibition is a rapidly growing discipline within drug discovery.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Compared with noncovalent inhibitors, covalent PPI inhibitors can have the advantages of sustained inhibition and longer residence times, as covalently bound PPI targets are persistently inhibited until protein degradation and regeneration [40].”
From The design and development of covalent protein-protein interaction inhibitors for cancer treatment (2020) · cites this paper as [40]
In the citing paper
“Covalent ligand screening is another ligand discovery approach that is becoming more common, whereby various methods are used to discover covalent ligands from libraries of electrophilic compounds7,12,13.”
From Advances in covalent drug discovery (2022) · cites this paper as [7]
In the citing paper
“include the Bruton’s tyrosine kinase (BTK) inhibitor ibrutinib (AbbVie) and the epidermal growth factor receptor (EGFR) inhibitor osimertinib (AstraZeneca), with sales totalling US$8.43 billion and $4.33 billion in 2020, respectively7,8.”
From Advances in covalent drug discovery (2022) · cites this paper as [7]
Citations
Cites
Drucker, D. J., & Nauck, M. A. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69705-5 · Cited by 3,896
Epidermal growth factor receptor mutations in lung cancer
Sharma, S. V., Bell, D. W., Settleman, J., & Haber, D. A. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2088 · Cited by 3,170
Targeting cancer with small molecule kinase inhibitors
Zhang, J., Yang, P. L., & Gray, N. S. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2559 · Cited by 2,576
K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions
Ostrem, J. M., Peters, U., Sos, M. L., Wells, J. A., & Shokat, K. M. (2013) · Nature · doi:10.1038/nature12796 · Cited by 2,557
Cross, D. A. E., Ashton, S. E., Ghiorghiu, S., Eberlein, C., Nebhan, C. A., Spitzler, P. J., Orme, J. P., Finlay, M. R. V., Ward, R. A., Mellor, M. J., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-0337 · Cited by 2,246
Self-citationComputational Methods in Drug Discovery
Sliwoski, G., Kothiwale, S., Meiler, J., & Lowe, E. W. (2014) · Pharmacological Reviews · doi:10.1124/pr.112.007336 · Cited by 2,160
The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP
Yun, C.-H., Mengwasser, K. E., Toms, A. V., Woo, M. S., Greulich, H., Wong, K.-K., Meyerson, M., & Eck, M. J. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0709662105 · Cited by 2,118
The resurgence of covalent drugs
Singh, J., Petter, R. C., Baillie, T. A., & Whitty, A. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3410 · Cited by 1,873
How were new medicines discovered?
Swinney, D. C., & Anthony, J. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3480 · Cited by 1,812
Thress, K. S., Paweletz, C. P., Felip, E., Cho, B. C., Stetson, D., Dougherty, B., Lai, Z., Markovets, A., Vivancos, A., Kuang, Y., et al. (2015) · Nature Medicine · doi:10.1038/nm.3854 · Cited by 1,589
Research works printed but not linked: 1
- Martin-Gago, 2017, Cell Chem. Biol., 24, e585
Cited by
Items 101–200 of 371
A Sulfonium Triggered Thiol-yne Reaction for Cysteine Modification
Hou, Z., Wang, D., Li, Y., Zhao, R., Wan, C., Ma, Y., Lian, C., Yin, F., & Li, Z. (2020) · The Journal of Organic Chemistry · doi:10.1021/acs.joc.9b02505 · Cited by 34
Xu, S., Ding, D., Zhang, X., Sun, L., Kang, D., Huang, B., Liu, X., & Zhan, P. (2022) · Molecules · doi:10.3390/molecules27030850 · Cited by 34
“The covalent binding with the target can be divided into two related but discontinuous processes: (i) the inhibitor reversibly binds to the target, making the functional groups on the weak electrophilic ligands adjacent to the specific nucleophilic residues on the protein; (ii) the ligand reacts with the functional gr…”
BackgroundEmerging drug design strategies in anti-influenza drug discovery
Liu, C., Hu, L., Dong, G., Zhang, Y., da Silva‐Júnior, E. F., Liu, X., Menéndez‐Arias, L., & Zhan, P. (2023) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2023.08.010 · Cited by 37
“The seeker interacts with the target protein in a non-covalent manner, while the warhead covalently binds to the amino acid residues in the target protein 53 .”
BackgroundDenis, J. D. S., Chessari, G., Cleasby, A., Cons, B. D., Cowan, S., Dalton, S. E., East, C., Murray, C. W., O’Reilly, M., Peakman, T. M., et al. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c01044 · Cited by 34
The pathogenic mechanism of Mycobacterium tuberculosis: implication for new drug development
Yan, W., Zheng, Y., Dou, C. R., Zhang, G., Arnaout, T., & Cheng, W. (2022) · Molecular Biomedicine · doi:10.1186/s43556-022-00106-y · Cited by 38
Gambini, L., Udompholkul, P., Salem, A. F., Baggio, C., & Pellecchia, M. (2020) · ChemMedChem · doi:10.1002/cmdc.202000355 · Cited by 32
Zhang, M., Aguilar, A., Xu, S., Huang, L., Chinnaswamy, K., Sleger, T., Wang, B., Größ, S., Nicolay, B., Ronseaux, S., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00789 · Cited by 31
Mechanism of activation and the rewired network: New drug design concepts
Nussinov, R., Zhang, M., Maloney, R., Tsai, C., Yavuz, B. R., Tunçbağ, N., & Jang, H. (2021) · Medicinal Research Reviews · doi:10.1002/med.21863 · Cited by 31
Inhibitors of Immune Checkpoints: Small Molecule- and Peptide-Based Approaches
Fuchs, N. S., Zhang, L., Calvo‐Barreiro, L., Kuncewicz, K., & Gabr, M. T. (2024) · Journal of Personalized Medicine · doi:10.3390/jpm14010068 · Cited by 29
“Designing small molecule-based covalent inhibitors rational reactivity and selectivity fi ne-tuning [69,70].”
BackgroundLysine Covalent Antagonists of Melanoma Inhibitors of Apoptosis Protein
Udompholkul, P., Baggio, C., Gambini, L., Alboreggia, G., & Pellecchia, M. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c01459 · Cited by 31
Covalent hits and where to find them
Lucas, S. C. C., Blackwell, J. H., Hewitt, S. H., Semple, H., Whitehurst, B. C., & Xu, H. (2024) · SLAS DISCOVERY · doi:10.1016/j.slasd.2024.01.003 · Cited by 31
“The primary reason for doing this was to disconnect the pharmacokinetics and pharmacodynamic parameters for a particular series and to compete with high intracellular concentrations of endogenous substrates such as ATP [13].”
BackgroundDesign of next-generation covalent inhibitors: Targeting residues beyond cysteine
Jones, L. H. (2020) · Annual reports in medicinal chemistry · doi:10.1016/bs.armc.2020.10.001 · Cited by 34
Structure–Reactivity Studies of 2-Sulfonylpyrimidines Allow Selective Protein Arylation
Pichon, M. M., Drelinkiewicz, D., Lozano, D., Moraru, R., Hayward, L. J., Jones, M., McCoy, M. A., Allstrum-Graves, S., Balourdas, D.-I., Joerger, A. C., et al. (2023) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.3c00322 · Cited by 29
“Among reported arylating agents, electrophiles 4,6- dimethyl-2-(methylsulfonyl)nicotinonitrile 11 and 4,6-dimeth- yl-2-(methylsulfonyl)-3-nitropyridine 12 , recently reported by Bollong et al., 29 were ca. 5 times less reactive than 4q .”
BackgroundProj, M., Knez, D., Sosič, I., & Gobec, S. (2022) · Drug Discovery Today · doi:10.1016/j.drudis.2022.03.008 · Cited by 32
Unveiling the Structural Insights into the Selective Inhibition of Protein Kinase D1
Dash, R., Arifuzzaman, M., Mitra, S., Hannan, M. A., Absar, N., & Hosen, S. M. Z. (2019) · Current Pharmaceutical Design · doi:10.2174/1381612825666190527095510 · Cited by 27
Innovative design and potential applications of covalent strategy in drug discovery
Tang, T., Luo, J., Zhang, D., Lü, Y., Liao, W., & Zhang, J. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.117202 · Cited by 27
Advances in sulfonyl exchange chemical biology: expanding druggable target space
Jones, L. H. (2025) · Chemical Science · doi:10.1039/d5sc02647d · Cited by 32
Jangid, K., Devi, B., Sahoo, A., Kumar, V., Dwivedi, A. R., Thareja, S., Kumar, R., & Kumar, V. (2023) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2023.2201838 · Cited by 30
“SBDD deals with the 3D structure of the target protein, its enzymatic cavity, and understanding of the disease at the molecular level (Lonsdale & Ward, 2018; Uniyal, Mahapatra, Tiwari, Sandhir, & Kumar et al., 2022).”
BackgroundShawky, A. M., Almalki, F. A., Alzahrani, H. A., Abdalla, A. N., Youssif, B. G. M., Ibrahim, N. A., Gamal, M., El-Sherief, H. A. M., Abdel‐Fattah, M. M., Hefny, A. A., et al. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116704 · Cited by 27
Huang, Y., Wei, L., Han, X., Chen, H., Ren, Y., Xu, Y., Song, R., Rao, L., Chen, S., Peng, C., et al. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.111749 · Cited by 24
Discovery of a novel covalent CDK4/6 inhibitor based on palbociclib scaffold
Shan, H., Ma, X., Yan, G., Luo, M., Zhong, X.-X., Lan, S., Yang, J., Liu, Y., Pu, C., Yu, T., et al. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113432 · Cited by 25
Arafet, K., Scalvini, L., Galvani, F., Martí, S., Moliner, V., Mor, M., & Lodola, A. (2023) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.2c01586 · Cited by 26
In situ antigen-capture strategies for enhancing dendritic cell-mediated anti-tumor immunity
Zheng, J., Li, X., He, A., Zhang, Y., Yang, Y., Dang, M., Li, Q., Mou, Y., & Dong, H. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.113984 · Cited by 27
Activatable covalent labeling probes: design, mechanism, and biological applications
Miao, Y., Tian, Y., & Ye, D. (2025) · Chemical Society Reviews · doi:10.1039/d5cs00984g · Cited by 26
Chen, F.-Y., Li, X., Zhan, G., Liu, H., Kang, B., Zhang, S.-C., Peng, C. Y., & Han, B. (2020) · Tetrahedron Letters · doi:10.1016/j.tetlet.2020.151806 · Cited by 24
Reversible covalent inhibitors suppress enterovirus 71 infection by targeting the 3C protease
Liu, M., Xu, B., Ma, Y., Shang, L., Ye, S., & Wang, Y. (2021) · Antiviral Research · doi:10.1016/j.antiviral.2021.105102 · Cited by 24
Covalent inhibitors of EZH2: Design, synthesis and evaluation
Zhang, Q., Chen, X., Hu, X., Duan, X., Wan, G., Li, L., Feng, Q., Zhang, Y., Wang, N., & Yu, L. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.112617 · Cited by 27
Wen, W., Cao, H., Huang, Y., Tu, J., Chen, W., Wan, J., Han, X., Chen, H., Liu, J., Rao, L., et al. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c02102 · Cited by 22
Protocol for Stereoselective Construction of Highly Functionalized Dienyl Sulfonyl Fluoride Warheads
Zhang, Z.-W., Wang, S., Fang, W., Lekkala, R., & Qin, H. (2020) · The Journal of Organic Chemistry · doi:10.1021/acs.joc.0c01877 · Cited by 23
Never Gonna Give You Up – Current Developments in Covalent Protein Kinase Inhibitors
Hillebrand, L., & Gehringer, M. (2022) · CHIMIA International Journal for Chemistry · doi:10.2533/chimia.2022.435 · Cited by 25
Covalent inhibitors of bacterial peptidoglycan biosynthesis enzyme MurA with chloroacetamide warhead
Grabrijan, K., Hrast, M., Proj, M., Dolšak, A., Zdovc, I., Imre, T., Petri, L., Ábrányi‐Balogh, P., Keserű, G. M., & Gobec, S. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114752 · Cited by 27
Podoll, T., Pearson, P. G., Kaptein, A., Evarts, J., de Bruin, G., Hoek, M. E.-V., de Jong, A., van Lith, B., Sun, H., Byard, S. J., et al. (2022) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.122.001116 · Cited by 28
Covalent Kinase Inhibitors: An Overview
Gehringer, M. (2020) · Topics in medicinal chemistry · doi:10.1007/7355_2020_103 · Cited by 27
Histidine-Covalent Stapled Alpha-Helical Peptides Targeting hMcl-1
Alboreggia, G., Udompholkul, P., Baggio, C., Muzzarelli, K. M., Assar, Z., & Pellecchia, M. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c00277 · Cited by 22
Catechol-based inhibitors of bacterial urease
Pagoni, A., Daliani, T., Macegoniuk, K., Vassiliou, S., & Berlicki, Ł. (2019) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2019.02.032 · Cited by 22
Discovery and optimization of covalent Bcl-xL antagonists
Mukherjee, H., Su, N., Belmonte, M. A., Hargreaves, D., Patel, J. S., Tentarelli, S., Aquila, B. M., & Grimster, N. P. (2019) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2019.126682 · Cited by 23
Design and SAR Analysis of Covalent Inhibitors Driven by Hybrid QM/MM Simulations
Lodola, A., Callegari, D., Scalvini, L., Rivara, S., & Mor, M. (2020) · Methods in molecular biology · doi:10.1007/978-1-0716-0282-9_19 · Cited by 25
Huang, Z., Luo, W., Li, W., Chen, P., Wang, Z., Chen, R., Wang, Y., Huang, W., & Liang, G. (2022) · Acta Pharmacologica Sinica · doi:10.1038/s41401-022-00928-0 · Cited by 27
“Some historical covalent inhibitors were considered undesirable due to potential toxicity issues [54].”
BackgroundTechnologies for Direct Detection of Covalent Protein–Drug Adducts
Mons, E., Kim, R. Q., & Mulder, M. P. C. (2023) · Pharmaceuticals · doi:10.3390/ph16040547 · Cited by 26
Liu, F., Liu, C., Chai, Q., Zhao, C., Meng, H., Xia, X., Yao, T., & Zhang, Y. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c00977 · Cited by 22
Discovery of reactive peptide inhibitors of human papillomavirus oncoprotein E6
Ye, X., Zhang, P., Tao, J., Wang, J. C. K., Mafi, A., Grob, N. M., Quartararo, A. J., Baddock, H. T., Chan, L. J. G., McAllister, F. E., et al. (2023) · Chemical Science · doi:10.1039/d3sc02782a · Cited by 30
Compain, G., Monsarrat, C., Blagojevic, J., Brillet, K., Dumas, P., Hammann, P., Kühn, L., Martiel, I., Engilberge, S., Oliéric, V., et al. (2024) · JACS Au · doi:10.1021/jacsau.3c00572 · Cited by 22
Covalent Targeting of Histidine Residues with Aryl Fluorosulfates: Application to Mcl-1 BH3 Mimetics
Alboreggia, G., Udompholkul, P., Atienza, E. L., Muzzarelli, K. M., Assar, Z., & Pellecchia, M. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c01541 · Cited by 21
Covalent-Allosteric Inhibitors: Do We Get the Best of Both Worlds?
Tao, H., Yang, B., Farhangian, A., Xu, K., Li, T., Zhang, Z., & Li, J. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c02760 · Cited by 22
Jackson, P. A., Schares, H. A. M., Jones, K. F. M., Widen, J. C., Dempe, D. P., Grillet, F., Cuellar, M. E., Walters, M. A., Harki, D. A., & Brummond, K. M. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01464 · Cited by 22
Covalent inhibitors: An ambitious approach for the discovery of newer oncotherapeutics
Cheke, R. S., & Kharkar, P. S. (2023) · Drug Development Research · doi:10.1002/ddr.22132 · Cited by 26
“The development of “ targeted covalent drugs ” has made significant advancements in the clinical setting, particularly in the past 15 years (Ghosh et al., 2019; Lonsdale & Ward, 2018; Singh et al., 2011).”
BackgroundBlackner, J. J., Schneider, O. M., Wong, W. O., & Hall, D. G. (2024) · Journal of the American Chemical Society · doi:10.1021/jacs.4c06360 · Cited by 20
Advancements, challenges, and future frontiers in covalent inhibitors and covalent drugs: A review
Hameed, M. S., Cao, H., Guo, L., Zeng, L., & Ren, Y. (2024) · European Journal of Medicinal Chemistry Reports · doi:10.1016/j.ejmcr.2024.100217 · Cited by 32
Evaluation of a Covalent Library of Diverse Warheads (CovLib) Binding to JNK3, USP7, or p53
Klett, T., Schwer, M., Ernst, L. N., Engelhardt, M. U., Jaag, S., Masberg, B., Knappe, C., Lämmerhofer, M., Gehringer, M., & Boeckler, F. M. (2024) · Drug Design Development and Therapy · doi:10.2147/dddt.s466829 · Cited by 23
Chen, T., Liu, Y., Shi, M., Tang, M., Si, W., Yuan, X., Wen, Y., & Chen, L. (2021) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2021.128433 · Cited by 20
Targeting Protein-Protein Interaction with Covalent Small-Molecule Inhibitors
Li, B., Rong, D., & Wang, Y. (2019) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026619666191011163410 · Cited by 22
Recent update on the development of EZH2 inhibitors and degraders for cancer therapy
Tang, M., Gong, M., Liu, X., Zhang, T., Liu, Z., & Song, D. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.118106 · Cited by 23
Wei, L., Wen, W., Rao, L., Huang, Y., Lei, M., Liu, K., Hu, S., Song, R., Ren, Y., & Wan, J. (2020) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.9b01197 · Cited by 20
Akher, F. B., Farrokhzadeh, A., & Soliman, M. E. S. (2018) · Chemistry & Biodiversity · doi:10.1002/cbdv.201800518 · Cited by 20
“Therefore, these inhibitors offer longer duration of action than non-covalent inhibitors, since EGFRDM will remain inhibited until the protein is degraded and then regenerated.[26] However, the additional covalent bond recovered inhibitory activity, the narrow selectivity window between EGFR wild-type”
BackgroundAl-Khawaldeh, I., Yasiri, M. J. A., Aldred, G. G., Basmadjian, C., Bordoni, C., Harnor, S. J., Heptinstall, A. B., Hobson, S. J., Jennings, C., Khalifa, S., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01249 · Cited by 19
Selective Covalent Targeting of Pyruvate Kinase M2 Using Arsenous Warheads
Wang, J., Zhou, S., Cheng, Y., Cheng, L., Qin, Y., Zhang, Z., Bi, A., Xiang, H., He, X., Tian, X., et al. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c01563 · Cited by 18
Overcoming challenges in developing small molecule inhibitors for GPVI and CLEC-2
Damaskinaki, F.-N., Morán, L. A., García, Á. G., Kellam, B., & Watson, S. P. (2021) · Platelets · doi:10.1080/09537104.2020.1863939 · Cited by 18
“These considerations also apply to small-molecule irreversible inhibitors, although these have the advantage of countering the avidity [45].”
BackgroundCovaDOTS: In Silico Chemistry-Driven Tool to Design Covalent Inhibitors Using a Linking Strategy
Hoffer, L., Sáez‐Ayala, M., Horvath, D., Varnek, A. A., Morelli, X., & Roche, P. (2019) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.8b00960 · Cited by 19
Synthetic Methodology-driven Chemical Protein Modifications
Maruyama, K., & Kanai, M. (2019) · Chemistry Letters · doi:10.1246/cl.190652 · Cited by 20
Revealing a Decisive Role for Secondary Coordination Sphere Nucleophiles on Methane Activation
Anderson, M. E., Braı̈da, B., Hiberty, P. C., & Cundari, T. R. (2020) · Journal of the American Chemical Society · doi:10.1021/jacs.9b12644 · Cited by 17
Banerjee, S. (2020) · Biophysical Chemistry · doi:10.1016/j.bpc.2020.106510 · Cited by 17
dos Santos, A. M., Oliveira, A. R. S., da Costa, C. H. S., Kenny, P. W., Montanari, C. A., Júnior, J. D. J. G. V., & Lameira, J. (2022) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.2c00466 · Cited by 18
Hasan, M. N., Ray, M., & Saha, A. (2023) · The Journal of Physical Chemistry B · doi:10.1021/acs.jpcb.3c04710 · Cited by 17
Targeted degradation of Pin1 by protein-destabilizing compounds
Alboreggia, G., Udompholkul, P., Rodriguez, I., Blaha, G. M., & Pellecchia, M. (2024) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2403330121 · Cited by 18
Du, L., Yee, S. S., Karthik, R., & Risinger, A. L. (2020) · Nature Communications · doi:10.1038/s41467-019-14277-w · Cited by 18
Recent applications of covalent chemistries in protein–protein interaction inhibitors
Chan, A. M., Goodis, C. C., Pommier, E. G., & Fletcher, S. (2022) · RSC Medicinal Chemistry · doi:10.1039/d2md00112h · Cited by 19
Discovery of Carbodiimide Warheads to Selectively and Covalently Target Aspartic Acid in KRASG12D
Sirocchi, L. S., Scharnweber, M., Oberndorfer, S., Siszler, G., Żak, K. M., Rumpel, K., Neumüller, R. A., & Wilding, B. (2025) · Journal of the American Chemical Society · doi:10.1021/jacs.5c03562 · Cited by 18
Wang, L., Zhang, Z., Yu, D., Yang, L., Li, L., He, Y., & Shi, J. (2023) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2023.106577 · Cited by 16
Erbay, T. G., Dempe, D. P., Godugu, B., Liu, P., & Brummond, K. M. (2021) · The Journal of Organic Chemistry · doi:10.1021/acs.joc.1c01335 · Cited by 15
Targeting cyclin-dependent kinases: From pocket specificity to drug selectivity
Huang, Y., Liu, W., Zhao, C., Shi, X., Zhao, Q., Jia, J., & Wang, A. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116547 · Cited by 19
Structure-Aided Computational Design of Triazole-Based Targeted Covalent Inhibitors of Cruzipain
Cerutti, J. P., Diniz, L. A., Santos, V. C., Larrea, S. C. V., Alonso, G., Ferreira, R. S., Dehaen, W., & Quevedo, M. A. (2024) · Molecules · doi:10.3390/molecules29174224 · Cited by 15
Acetylation of the Catalytic Lysine Inhibits Kinase Activity in PI3Kδ
Fournier, J. C. L., Evans, J. P., Zappacosta, F., Thomas, D. A., Patel, V. K., White, G. V., Campos, S., & Tomkinson, N. C. O. (2021) · ACS Chemical Biology · doi:10.1021/acschembio.1c00225 · Cited by 19
Pei, J., Wang, G., Wang, A., Wu, C., Pan, X., Wen, S., Bu, F., Zhu, Y., Wang, Y., Ouyang, L., et al. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c00027 · Cited by 15
Profiling and Optimizing Targeted Covalent Inhibitors through EGFR-Guided Studies
Damghani, T., Chitnis, S. P., Abidakun, O. A., Patel, K. B., Lin, K. S., Ouellette, E. A., Lantry, A. M., & Heppner, D. E. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c01661 · Cited by 14
Dou, D., Diao, Y., Sha, W., Su, R., Tong, L., Li, W., Leng, L., Xie, L., Yu, Z., Song, H., et al. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c02208 · Cited by 13
Stein, A., Thomopoulou, P. H. N., Frias, C., Pütz, S. M., Varela, P. F., Wilke, N. L., Mariappan, A., Neudörfl, J., Fedorov, A. Y., Gopalakrishnan, J., et al. (2022) · ACS Omega · doi:10.1021/acsomega.1c04659 · Cited by 14
Columbus, I., Ghindes‐Azaria, L., Herzog, I. M., Blum, E., Parvari, G., Eichen, Y., Cohen, Y., Gershonov, E., Drug, E., Saphier, S., et al. (2023) · Communications Chemistry · doi:10.1038/s42004-023-01004-2 · Cited by 13
“T he rational design of covalent drugs has drawn increased attention in recent years 1,2 , mainly due to the shift from covalent inhibitors that exploit the catalytic machinery of enzymes to targeting non-catalytic residues 3 .”
InfluentialXiao, M., Zhu, M., Wu, S., Ma, L., Qi, L., Ha, S., Xiong, S., Chen, M., Chen, D., Luo, G., et al. (2022) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2022.106263 · Cited by 12
Catalysis medicine: Participating in the chemical networks of living organisms through catalysts
Kanai, M., & Takeuchi, Y. (2022) · Tetrahedron · doi:10.1016/j.tet.2022.133227 · Cited by 12
Elemental exchange: Bioisosteric replacement of phosphorus by boron in drug design
Mehta, N. V., Abhyankar, A. N., & Degani, M. S. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115761 · Cited by 13
Reactive Docking: A Computational Method for High-Throughput Virtual Screenings of Reactive Species
Bianco, G., Holcomb, M., Santos‐Martins, D., Tillack, A. F., Hansel-Harris, A., & Forli, S. (2023) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.3c00832 · Cited by 12
Zhao, Y., Zhao, X., Duan, L., Hou, R., Gu, Y., Liu, Z., Chen, J., Wu, F., Yang, L., Le, X. C., et al. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c02076 · Cited by 11
Advanced technologies for screening and identifying covalent inhibitors
Guo, Y., Wen, S., Tong, A., & Wang, Y. (2024) · TrAC Trends in Analytical Chemistry · doi:10.1016/j.trac.2024.117833 · Cited by 12
Cai, G., Bao, Y., Li, Q., Hsu, P., Xia, J., & Ngo, J. C. K. (2024) · Communications Chemistry · doi:10.1038/s42004-024-01230-2 · Cited by 11
“Most covalent inhibitors target cysteine due to its high nucleophilicity 46 .”
Moraru, R., Valle‐Argos, B., Minton, A. R., Buermann, L. E., Pan, S., Wales, T. E., Joseph, R. E., Andreotti, A. H., Strefford, J. C., Packham, G. K., et al. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c01927 · Cited by 12
Zhao, Y., Zhang, M., Hou, X., Han, J., Qin, X., Yang, Y., Song, Y., Liu, Z., Zhang, Y., Xu, Z., et al. (2023) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2023.117413 · Cited by 11
QM/MM and molecular dynamics investigation of the mechanism of covalent inhibition of TAK1 kinase
Toviwek, B., Gleeson, D., & Gleeson, M. P. (2021) · Organic & Biomolecular Chemistry · doi:10.1039/d0ob02273j · Cited by 11
Precious Cargo: The Role of Polymeric Nanoparticles in the Delivery of Covalent Drugs
Weissberger, D., Stenzel, M. H., & Hunter, L. (2024) · Molecules · doi:10.3390/molecules29204949 · Cited by 12
“Covalent drugs can be advantageous for treating diseases in which high target occupancy is important, such as cancer and bacterial infections [2,3].”
BackgroundInfluentialA patent review of CYP3A4 inhibitors (2018 – present)
Tu, D., Hu, X., Lei, J.-X., Liu, S., Xiao, Z.-P., Yang, L., & Ge, G. (2025) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2025.2470294 · Cited by 10
Rational Design and Identification of ISM7594 as a Tissue-Agnostic FGFR2/3 Inhibitor
Wang, Y., Liu, J., Zhang, Y., Zhao, J., Wang, C. W. C., Cui, H. S., Meng, F., Aliper, A. M., Liang, T., Yan, F., et al. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c00928 · Cited by 11
Huang, F., Hu, H., Wang, K., Peng, C., Xu, W., Zhang, Y., Gao, J., Liu, Y., Zhou, H., Huang, R., et al. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c00372 · Cited by 11
Discovery of lysosome-targeted covalent anticancer agents based on isosteviol skeleton
Liu, J., Li, L., Li, X., Wang, X., Zhao, X., Qiao, Y., Xu, Y., Sun, Y., Qian, L., Liu, Z., et al. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112896 · Cited by 10
Endres, E., Chen, N. Y., & Sotriffer, C. (2023) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.3c00061 · Cited by 9
Bonus, M., Greb, J., Majmudar, J. D., Boehm, M., Korczynska, M., Nazemi, A., Mathiowetz, A. M., & Gohlke, H. (2025) · Journal of Molecular Biology · doi:10.1016/j.jmb.2025.169196 · Cited by 13
Watanabe, S., Tokunaga, K., Tanaka, Y., Hirose, Y., Mishiro‐Sato, E., Kano, K., Sasaki‐Tabata, K., Kato, Y., Nishida, M., Shindo, N., et al. (2025) · Journal of the American Chemical Society · doi:10.1021/jacs.5c07422 · Cited by 11
Covalent drug – An emerging framework for targeted drug development
Bhole, R. P., Joshi, G. O., Kapare, H. S., Chikhale, R. V., & Chaudhari, S. Y. (2024) · Results in Chemistry · doi:10.1016/j.rechem.2024.101615 · Cited by 13
Covalent fragment libraries in drug discovery—Design, synthesis, and screening methods
Hocking, B. J. W., Armstrong, A., & Mann, D. J. (2023) · Progress in medicinal chemistry · doi:10.1016/bs.pmch.2023.10.003 · Cited by 13
Electrophile Scanning Reveals Reactivity Hotspots for the Design of Covalent Peptide Binders
Grob, N. M., Remarcik, C., Rössler, S. L., Wong, J. Y. K., Wang, J. C. K., Tao, J., Smith, C. L., Loas, A., Buchwald, S. L., Eaton, D., et al. (2023) · ACS Chemical Biology · doi:10.1021/acschembio.3c00538 · Cited by 9
Lin, W., Wang, P., Zhang, Y., Lü, W., Yang, M., Zhu, Z., Yin, X., Lv, J., Zheng, Z., Mei, S., et al. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c01663 · Cited by 13
Graph neural networks for identifying protein-reactive compounds
Gil, V., & Rowley, C. N. (2024) · Digital Discovery · doi:10.1039/d4dd00038b · Cited by 9
Metadata
- Authors
- Lonsdale, R., & Ward, R. A.
- Affiliations
- AstraZeneca (United Kingdom) (GB)
- Corresponding author
- Ward, Richard A.
- Venue
- Chemical Society Reviews
- Publisher
- Royal Society of Chemistry (RSC)
- Published
- 2018
- Volume
- 47
- Issue
- 11
- Pages
- 3816-3830
- ISSN
- 0306-0012 (ISSN-L)
- 1460-4744
- OpenAlex
- W2796108867
- Cited by
- 344
- References
- 49
- Citations by year
- 2026: 30 · 2025: 42 · 2024: 46 · 2023: 49 · 2022: 47 · 2021: 45 · 2020: 46 · 2019: 31 · 2018: 8
- FWCI
- 2.71
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Chemical Society Reviews (publishedVersion)
- PubMed (publishedVersion)
- Funders
- AstraZeneca
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Physical Sciences › Chemistry › Organic Chemistry › Click Chemistry and Applications
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
- Keywords
- targeted covalent inhibitors, covalent inhibition, structure-based drug design, reactive functional groups, small molecule inhibitors, inhibitor selectivity, covalent drug discovery
- MeSH terms
- Humans, Drug Design, Molecular Structure, Small Molecule Libraries
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.